Last reviewed · How we verify
placebo treatment during 3 days
Placebo produces therapeutic effects through patient expectation and psychological mechanisms rather than active pharmacological action.
Placebo produces therapeutic effects through patient expectation and psychological mechanisms rather than active pharmacological action. Used for Research/clinical trial control arm (non-therapeutic use).
At a glance
| Generic name | placebo treatment during 3 days |
|---|---|
| Also known as | lactose |
| Sponsor | St. Olavs Hospital |
| Modality | Small molecule |
| Phase | FDA-approved |
Mechanism of action
Placebo treatment leverages the placebo effect, wherein a patient's belief in receiving treatment triggers neurobiological and psychological responses that can improve symptoms or outcomes. This occurs through expectation-driven activation of endogenous pain-relief pathways, immune modulation, and symptom perception changes. The effect is particularly pronounced in conditions with subjective symptom components such as pain, nausea, and fatigue.
Approved indications
- Research/clinical trial control arm (non-therapeutic use)
Common side effects
- Nocebo effects (symptom worsening due to negative expectation)
- Disappointment or distress upon learning treatment was placebo
Key clinical trials
- Study of Oral Idebenone to Treat Non-Alcoholic Steatohepatitis (PHASE1, PHASE2)
- Venetoclax or Placebo in Combination With Reduced-Intensity Conditioning Hematopoietic Cell (Bone Marrow/Blood Stem Cell) Transplant and as Maintenance Therapy After Transplant in Patients With Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial) (PHASE2)
- MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial) (PHASE2)
- Phase III Study of Induction and Consolidation Chemotherapy With Venetoclax in Patients With Newly Diagnosed AML or MDS-EB-2 (PHASE3)
- Testing the Addition of a New Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiotherapy in Patients With Locally Advanced Pancreatic Cancer (PHASE1, PHASE2)
- Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer (PHASE3)
- Assessment of TetraSOD® Efficacy to Improve Semen Parameters in Men With Idiopathic Infertility (NA)
- Using Nivolumab Alone or With Cabozantinib to Prevent Mucosal Melanoma Return After Surgery (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- placebo treatment during 3 days CI brief — competitive landscape report
- placebo treatment during 3 days updates RSS · CI watch RSS
- St. Olavs Hospital portfolio CI